Chinese Academy of Sciences (CAS) Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Savaid Medical School, University of Chinese Academy of Sciences, Beijing, China.
Front Cell Infect Microbiol. 2023 Jun 2;13:1183590. doi: 10.3389/fcimb.2023.1183590. eCollection 2023.
Drug-resistant tuberculosis (DR-TB) in children is a growing global health concern, This review provides an overview of the current epidemiology of childhood TB and DR-TB, including prevalence, incidence, and mortality. We discuss the challenges in diagnosing TB and DR-TB in children and the limitations of current diagnostic tools. We summarize the challenges associated with treating multi-drug resistance TB in childhood, including limitations of current treatment options, drug adverse effects, prolonged regimens, and managing and monitoring during treatment. We highlight the urgent need for improved diagnosis and treatment of DR-TB in children. The treatment of children with multidrug-resistant tuberculosis will be expanded to include the evaluation of new drugs or new combinations of drugs. Basic research is needed to support the technological development of biomarkers to assess the phase of therapy, as well as the urgent need for improved diagnostic and treatment options.
儿童耐多药结核病（DR-TB）是一个日益严重的全球卫生关注问题。本文综述了儿童结核病和耐多药结核病的当前流行病学，包括患病率、发病率和死亡率。我们讨论了儿童结核病和耐多药结核病诊断方面的挑战，以及当前诊断工具的局限性。我们总结了与儿童耐多药结核病治疗相关的挑战，包括当前治疗方案的局限性、药物不良反应、延长疗程以及治疗期间的管理和监测。我们强调了迫切需要改善儿童耐多药结核病的诊断和治疗。将扩大儿童耐多药结核病的治疗范围，包括评估新的药物或新的药物组合。需要开展基础研究，以支持治疗阶段的生物标志物评估技术的发展，同时迫切需要改进诊断和治疗选择。
